Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

21.02.2018 | case report | Ausgabe 1/2018 Open Access

memo - Magazine of European Medical Oncology 1/2018

Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 1/2018
Autoren:
MBBCh Malik Ghannam, MS Maria Bryan, DO Erik Kuross, MD/PhD Brent Berry
Wichtige Hinweise

Authors’ contributions

M. Ghannam, M. Bryan, and B. Berry were responsible for the clinical management of the patient. M. Bryan and E. Kuross participated in the data collection and case writing. B. Berry participated in the analysis and interpretation of data. M. Ghannam participated in the critical revision of manuscript for intellectual content and study supervision.

Availability of data and materials

All the data supporting our findings is contained within the manuscript.

Summary

Background

Primary malignant pleural effusion has been reported in about 134 cases of multiple myeloma (MM). Associated pleural effusions in cases of MM portend a poor prognosis and identifying them is highly relevant. Reported is the case of a man diagnosed with MM who developed primary myelomatous pleural effusion in the setting of multiple relapses and subsequent mortality within 2 months of the pleural effusion diagnosis.

Presentation

A 61-year-old African American man was diagnosed with MM in 2011. He received induction therapy of lenalidomide and dexamethasone and an autologous stem cell transplant in 2012. Over the next 5 years, the patient went through alternating periods of remission and relapse that were treated with two rounds of thoracic spine radiation therapy and chemotherapeutic agents. In September 2017, the patient presented with worsening dyspnea and was found to have pleural effusion. Fluid analysis showed plasma cell dyscrasia. Fluid drainage was performed, then the patient was discharged after 1 week which was followed by rapid re-accumulation of fluid and rehospitalization about 10 days after discharge. The patient passed away a few weeks after the second admission.

Conclusion

Pleural effusion carries a differential diagnosis which may include malignancy but is commonly thought to be less specific to multiple myeloma but should still remain in the differential diagnosis. To our knowledge, this is the first case of myelomatous pleural effusion (MPE) that was reported after multiple relapses of MM. MPE is a very rare complication of MM, and its presence is a strong indicator of imminent mortality and need for comfort care in case of multiple relapses. End-stage pleural effusion in MM in the setting of proteasome inhibitor adds more therapeutic and diagnostic challenges.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

memo - Magazine of European Medical Oncology 1/2018Zur Ausgabe